David John Kuter, MD, DPhil
Director, Center for Hematology
My passion for hematology is based on my belief that scientific concepts can be usually applied at the bedside to provide patients with personalized, attentive care. But when science fails, a compassionate and soothing word may be equally helpful.
- Department of Medicine
- Clinical Interests
- Platelet Disorders
- Thrombosis and hemostasis
- Polycythemia vera
- Essential thrombocytosis
- Myeloproliferative diseases
- Coagulation disorders
- Gaucher's disease
- Chronic myeloid leukemia
- Monoclonal gammopathy of unknown significance
- Boston: Massachusetts General Hospital
- Medical Education
- MD, Harvard Medical School
- D.Phil., Oxford University
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Hematology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
- Accepting New Patients
- Accepting New Patients
- Insurances Accepted
- Aetna Health Inc.
Blue Cross Blue Shield - Blue Care 65
Blue Cross Blue Shield - Indemnity
Blue Cross Blue Shield - Managed Care
Blue Cross Blue Shield - Partners Plus
Cigna (PAL #'s)
Fallon Community HealthCare
Great-West Healthcare (formally One Health Plan)
Harvard Pilgrim Health Plan - ACD
Harvard Pilgrim Health Plan - PBO
Health Care Value Management (HCVM)
Humana/Choice Care PPO
Medicare - ACD
Neighborhood Health Plan - ACD
Neighborhood Health Plan - PBO
OSW - Maine
OSW - New Hampshire
OSW - Rhode Island
Private Health Care Systems (PHCS)
Railroad Medicare - ACD
Senior Whole Health
Tufts Health Plan
United Healthcare (non-HMO) - ACD
United Healthcare (non-HMO) - PBO
BiographyDr. David Kuter is Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He received his undergraduate degree from Harvard College and his D. Phil. in Biochemistry while a Rhodes Scholar at Oxford University, before obtaining his medical degree from Harvard Medical School. Dr. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of hematological disorders, and clinical research of thrombopoietic agents. His basic science group was one of the labs that discovered thrombopoietin and his clinical research group carried out seminal studies using thrombopoietic agents in transfusion medicine and immune thrombocytopenia (ITP). Dr Kuter is recipient of a number of awards, including the Irving London Teaching Award at Harvard Medical School, the Alfred Kranes Teaching Award at the Massachusetts General Hospital, the Douglas Family Foundation Prize for Research (2008 and 2010) at Massachusetts General Hospital, the Jane Green Memorial Prize for Teaching at the Massachusetts General Hospital, and the 2013 Earnest Beutler Award from the American Society of Hematology. He has given over 500 invited lectures in over 50 countries and served as Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, and New Haven. Dr Kuter has authored or co-authored over 300 articles published in international peer-reviewed journals such as The Lancet, The New England Journal of Medicine and Blood.
ResearchCurrent areas of ongoing research:
- Hereditary hemorrhagic telangiectasis (HHT): NIH sponsored grant to assess effect of pamolidomide to reduce bleeding in patients with HHT.
- Immune thrombocytopenia (ITP): NIH sponsored grant to assess effect of addition of mycophenolyate to standard of care for patients with ITP.
- Heparin-induced thrombocytopepenia (HIT): lead in 17 center NIH-sponsored study of the natural history and treatment of HIT
- Polycythemia vera (P.vera): Incyte Corp study (Reveal Study) to assess the natural history, treatment and quality of life of patients with P. vera.
- ITP: Ph 1 study using anti-CD40 ligand antibody (BMS sponsor) to reduce the rate of thrombocytopenia in patients with ITP
- ITP: Ph 1 study assessing the use of Staph protein A (Protalix, Inc) in the treatment of ITP
- ITP: assessment of patients with ITP treated with TPO receptor agonists--effect on longterm remission
- ITP: assessment of TPO receptor agonists in raising the platelet count of thrombocytopenic patients about to have surgery
- ITP: study of platelet function in patients with ITP after treatment with romiplostim
- Autoimmune hemolytic anemia (AIHA): creator and major site for international registry for patients with this disorder.
PublicationsSelected peer-reviewed publications (of over 300)
- Kuter DJ, Beeler D, Rosenberg RD. The purification and characterization of megapoietin: a megakaryocyte growth promoting protein. Proc Natl Acad Sci 1994;91:11104-11108.
- Kuter DJ, et al. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Humana Press, New York, 1997.
- Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. AlphaMed Press, Miamisburg, OH, 1998.
- Bussel J, Kuter DJ, George J, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J,Wasser J, Wiznitzer I, Kelly R, Chen CF, Nichol J. AMG 531, a thrombopoiesis-stimulating protein, for ITP. New Engl J Med 2006;355:1672-1681.
- Kuter DJ, et al. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. Lancet 2008;371:395-403.
- Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. NEJM 2010;363:1889-1899.
A new study finds that an FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment and significantly improving their quality of life.
55 Fruit Street
Boston, MA 02114-2696
Phone 2: 617-726-8033
Call the Massachusetts General Hospital physician referral service at 800-711-4644.
Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.
Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.